Molecular targeted therapy drugs are recommended as first-line treatment options for advanced NSCLC if sensitive EGFR gene mutations or ALK gene fusions are detected [3–6], because of their higher efficacy and lower toxicity than standard chemotherapy in these patients [8, 22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.